A Case of 5-Fluorouracil Induced Encephalopathy

被引:15
作者
Kwon, Kyung A. [1 ]
Kwon, Hyuk-Chan [1 ]
Kim, Min Chan [2 ]
Kim, Sung-Hyun [1 ]
Oh, Sung Yong [1 ]
Lee, Suee [1 ]
Kim, Hyo-Jin [1 ]
机构
[1] Dong A Univ, Dept Internal Med, Coll Med, Pusan 602715, South Korea
[2] Dong A Univ, Dept Surg, Coll Med, Pusan 602715, South Korea
来源
CANCER RESEARCH AND TREATMENT | 2010年 / 42卷 / 02期
关键词
5-FU; Neurotoxicity; Encephalopathy;
D O I
10.4143/crt.2010.42.2.118
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at risk for experiencing serious adverse effects following 5-fluorouracil (5-FU) based chemotherapy. Neurotoxicity is considered an extremely rare side effect of 5-FU. We report here on an unusual case of 5-FU induced encephalopathy. A 38-year-old woman with advanced gastric carcinoma was treated with adjuvant chemotherapy that consisted of infused 5-FU (1,000 mg/m(2)) for 5 days and cisplatin (60 mg/m2) on day 1 following total gastrectomy. Nineteen days after starting chemotherapy, the patient displayed a sudden onset of slurred speech, confusion, cognitive disturbances and paranoia. A magnetic resonance image (MRI) of the brain showed no structural abnormalities, and the other laboratory tests provided no explanations for her symptoms, other than a slightly elevated ammonia level. The patient was treated with a lactulose retention enema and thiamine infusion, the 5-FU was halted and her symptoms then recovered after 7 days.
引用
收藏
页码:118 / 120
页数:3
相关论文
共 12 条
[1]  
Baek Jin Ho, 2006, Korean Journal of Internal Medicine, V21, P43
[2]  
Cheung WY, 2008, CURR ONCOL, V15, P234
[3]   A Case of Wernicke's Encephalopathy Following Fluorouracil-based Chemotherapy [J].
Cho, In Jeong ;
Chang, Hye Jung ;
Lee, Kyoung Eun ;
Won, Hye Sung ;
Choi, Moon Young ;
Nam, Eun Mi ;
Mun, Yeung-Chul ;
Lee, Soon Nam ;
Seong, Chu-Myong .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2009, 24 (04) :747-750
[4]   POPULATION STUDY OF DIHYDROPYRIMIDINE DEHYDROGENASE IN CANCER-PATIENTS [J].
ETIENNE, MC ;
LAGRANGE, JL ;
DASSONVILLE, O ;
FLEMING, R ;
THYSS, A ;
RENEE, N ;
SCHNEIDER, M ;
DEMARD, F ;
MILANO, G .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2248-2253
[5]   5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development [J].
Grem, JL .
INVESTIGATIONAL NEW DRUGS, 2000, 18 (04) :299-313
[6]  
HEGGIE GD, 1987, CANCER RES, V47, P2203
[7]  
HEIER MS, 1989, ANTICANCER RES, V9, P1073
[8]   Intermediate dose 5-fluorouracil-induced encephalopathy [J].
Kim, YA ;
Chung, HC ;
Choi, HJ ;
Rha, SY ;
Seong, JS ;
Jeung, HC .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (01) :55-59
[9]   BIOCHEMICAL BASIS FOR FLUOROURACIL NEUROTOXICITY [J].
KOENIG, H ;
PATEL, A .
ARCHIVES OF NEUROLOGY, 1970, 23 (02) :155-&
[10]   Fluorouracil-induced neurotoxicity [J].
Pirzada, NA ;
Ali, II ;
Dafer, RM .
ANNALS OF PHARMACOTHERAPY, 2000, 34 (01) :35-38